Page 286 - Manual Of SOP
P. 286

Determination of Non Injurious Price

               or unit of the same organization for manufacturing of another product. In other
               words, intermediate products manufactured in the same company and used for the
               manufacture of PUC in the same company are called captive inputs.


               9.6.30. The captive input can be transferred to the next process either at cost or at
               market value. While computing the costs of such captive inputs, principles prescribed
               under Annexure-III must be followed i.e., optimization needs to be done for such
               captive inputs as well before allowing the return. Similarly, expenses disallowed
               under Annexure-III should not be included.

               9.6.31. If captive inputs are transferred at market rates, no return is allowed on
               assets used for the manufacture of captive inputs. Otherwise, proportionate NFA
               attributable to that input is apportioned to PUC for return purpose. Working Capital
               (WC) being allocated to different products / PUC on the turnover basis takes care of
               the portion of working capital allocable to captive input. If the DI accounts for the
               captively produced inputs at the cost of production, an additional return @ 22% on
               capital employed for assets utilized for producing such inputs is also allowed. In case
               the company transfers the captively produced inputs at market value consistently
               and shows it as such in the books of accounts, then such market value of captively
               produced inputs may be is adopted for determination of NIP.

               9.6.32. It may be added here that the cost details need to be collected for all major
               captive inputs used in the production of PUC, irrespective of the basis of pricing.

               9.5.33. When the petitioner insists to value the captively manufactured goods at
               a market price and doesn’t claim a return on capital employed for the captively
               manufactured product, the reasonability of market price in all such cases be
               preferably confirmed from the sale price of such goods to the independent buyers.


               TREATMENT OF R&D EXPENSES
               9.6.34. R&D expenses form part of costs that benefit the future as well as current
               production. If products under anti-dumping are not very high tech, R&D costs will
               normally form a small portion of total costs in NIP workings based on the actual
               amount booked under the head during POI.

               9.6.35. Para (4)(vii)(a) of Annexure-III provides that research and development
               expenses unless claimed  and substantiated  as relating  to the product-specific
               research, shall not be considered while assessing non-injurious price. In other




                                                 263
   281   282   283   284   285   286   287   288   289   290   291